Global Swab and Viral Transport Medium Market to Reach USD 2.2 Billion by 2030 on Back of COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 03 Dec 2020 |

Illustration
The global swab and viral transport medium (VTM) market was valued at USD 0.9 billion in 2019 and will witness a moderate growth rate of ~3% from 2020 to 2030 to reach USD 2.2 billion by 2030, driven by the onslaught of COVID-19 and increasing R&D activities.
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
Proteomic Risk Score Predicts Kidney Disease Progression in High-Risk Patients
Chronic kidney disease progression is difficult to anticipate, limiting opportunities to intervene before irreversible decline. Risk assessment is especially uncertain for people who carry high‑risk variants... Read more
Risk Prediction Tool Enhances Genetic Testing for Li-Fraumeni Syndrome
Li-Fraumeni syndrome is a rare hereditary cancer predisposition most often driven by germline mutations in the TP53 tumor suppressor gene. Determining who should receive TP53 testing remains challenging... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read more
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more








